SUMMARY
Patients with isolated functional or recurrent tricuspid regurgitation are often denied surgery because they are considered to be at high risk. Transcatheter valve therapy provides a less invasive alternative for tricuspid regurgitation associated with right heart failure. We have evaluated the feasibility of transcatheter tricuspid valve implantation of the NaviGate valved stent in a long-term swine model. The valved stent was successfully implanted through transjugular and transatrial approaches on the beating heart with excellent hemodynamic and valve performance. No conduction disturbance or coronary obstruction was observed. This technology could provide an alternative treatment for patients who are at high surgical risk with severe tricuspid regurgitation and However, the optimal timing and surgical technique to eliminate TR remains undefined, showing that tricuspid valve (TV) disease is not only underdiagnosed, but is also often surgically ignored. For many years it was believed that secondary TR would improve after mitral valve surgery alone, and it was consequently undertreated (4) . Thus, for example, in 1967, Braunwald et al. (5) recommended conservative nonsurgical management of "functional" TR. In the 1980s, it was observed that patients who had undergone successful mitral surgery sometimes returned years later with severe symptomatic TR and right heart failure. When these patients underwent reoperation, mortality was high (3) . More recently, compelling data have shown that surgically untreated secondary TR can persist or even worsen despite correction of the associated left-sided lesion (6) , suggesting that due to the severity and progressive course of the disease, an aggressive approach toward secondary TR is warranted (7, 8) . Unfortunately, this approach is rarely used, so patients usually do not undergo TV reoperations for secondary or recurrent TR, leading to high mortality rates due to worsening right heart failure (9).
In general, most of these patients present with renal impairment, severe pulmonary hypertension, and cardiac cirrhosis late in the disease state; given their coagulopathic state and low likelihood of improvement of right ventricular (RV) function in the perioperative period, they become high-risk surgical candidates.
Thereby, transcatheter approaches to TV disease could become an attractive alternative solution for these patients who present a burgeoning clinical unmet need for therapeutic advances. In addition, less invasive strategies may allow for earlier surgical treatment of TR, which may improve functional capacity and reduce end-organ dysfunction.
The NaviGate bioprosthesis (NaviGate Cardiac Structures Inc., Irvine, California) was designed exclusively to overcome the technical challenges associated with transcatheter valve implantation for these high-risk patients. Herein, we describe the preclinical feasibility study of a new transcatheter self-expanding bioprosthetic TV, implanted in a chronic porcine model using transcatheter and minimally invasive approaches on a beating heart with a sutureless valve implantation technique.
METHODS
NaviGate BIOPROSTHESIS. The NaviGate atrioventricular valve is a biological valved stent; it consists of a specifically configured Nitinol alloy stent into which is mounted a trileaflet valvular mechanism fabricated from equine pericardium that has been fixed in low concentrations of buffered glutaraldehyde ( Figures 1A   to 1D ). The configuration of the stent is specifically designed in a geometry that engages the tricuspid annulus (TA) and TV leaflets from both inferior and superior aspects and maintains a minimal extension Navia et al.
into both the atrium and ventricle to avoid flow dynamics alterations. Thus, the inferior aspect or ventricular diameter is designed to match the dilated tricuspid annulus typical of secondary TR, which has a mean diametric dimension of 40 AE 5 mm for most patients. For this experimental study, the superior or atrial size of the valve stent is maintained at 30 mm in diameter, and the inferior or ventricular diameter at 40 mm, ensuring that transvalvular gradients will be normal for a TV (DP mean #5 mm Hg) at normal flows. EXPERIMENTAL DESIGN. I n v i v o a s s e s s m e n t o f s a f e t y . These studies were designed both to assess the safety of the NaviGate device and to obtain a partial assessment of its effectiveness in performing the designed function; the latter assessment aimed to provide sufficient safety data for the first-in-human evaluation. Table 1) .
Previously a series of 6 NaviGate tricuspid valved stents were implanted in 6 healthy swine (n ¼ 6; 95 to 105 kg) in the TV orthotopic position for a long-term preclinical study using a minimally invasive right thoracotomy approach on a beating heart with a sutureless implantation technique ( Table 2 ). All valve prostheses used in this study have equivalent design and fabrication methods, and they were evaluated in a pulsatile mock circulatory loop for hemodynamic performance and quality control. The long-term study also assesses the replicability of both implantation approaches, the valved stent's suitability to Number of animals 6 transjugular
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incisions were closed in layers in the usual fashion.
The animals recovered in the acute care unit after the procedure. All animals were followed clinically for manifestation of heart failure and with serial echo- 
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Transcatheter Tricuspid Valve Replacement Navia et al. A Faxitron x-ray cell was used to visualize the position of the valved stent within the tricuspid apparatus in the resected rinsed heart, which identified no distortion or fracture of any of the segments or stent elements in the long-term study.
DISCUSSION
Tricuspid valve disease continues to present a challenging problem to cardiovascular specialists, especially in patients who develop TR associated with RV dysfunction and right heart failure (RHF) (11, 12) .
Recently, a more aggressive approach has been promoted for treatment of functional TR during left heart valve surgery to avoid high-risk reintervention thereafter (13) (14) (15) . Patients who present for isolated TV surgery are at high risk of mortality, especially with RV dysfunction and reoperation (16) (17) (18) . This could be attributed to RHF phenomena in the setting of long-standing TR that includes systemic venous congestion, volume overload, renal dysfunction, liver congestion, hypersplenism, and severe coagulopathy. concerns were raised for transcatheter caval devices that include persistent right heart volume overload, RV failure, and atrial arrhythmia; however, these concerns were not evidenced on early results (22, 23) .
The 
